Cargando…

Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis

OBJECTIVE: This study investigated payments made by pharmaceutical companies to oncology specialists in Japan, what the payments were for and whether the receipt of such payments contravened any conflict of interest (COI) regulations. DESIGN, SETTING AND PARTICIPANTS: Payment data to physicians, as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozaki, Akihiko, Saito, Hiroaki, Onoue, Yosuke, Sawano, Toyoaki, Shimada, Yuki, Somekawa, Yurie, Tsuji, Aritsune, Tanimoto, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Ethics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731803/ https://www.ncbi.nlm.nih.gov/pubmed/31494604 http://dx.doi.org/10.1136/bmjopen-2018-028805

Ejemplares similares

Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Kusumi, Eiji, et al.
Publicado: (2022)

Pharmaceutical company payments to the authors of the Japanese dementia clinical practice guidelines in 2016
por: Shimada, Yuki, et al.
Publicado: (2019)

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan
por: Sawano, Toyoaki, et al.
Publicado: (2019)

Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension
por: Senoo, Yuki, et al.
Publicado: (2021)

Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
por: Murayama, Anju, et al.
Publicado: (2020)

Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan
por: Saito, Hiroaki, et al.
Publicado: (2019)

Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies
por: Murayama, Anju, et al.
Publicado: (2021)

How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan
por: Ozaki, Akihiko, et al.
Publicado: (2022)

Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians
por: Murayama, Anju, et al.
Publicado: (2022)

Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?
por: Kobashi, Yurie, et al.
Publicado: (2019)

Will initial consultation patterns among undiagnosed cancer patients be the same after this COVID-19 pandemic? Experiences from the 2011 triple disaster in Fukushima, Japan
por: Ozaki, Akihiko, et al.
Publicado: (2020)

The Sun Is Still Shining: Nature of Industry Payments to Transplant Surgeons From 2014 to 2019
por: Lombardi, Conner V., et al.
Publicado: (2022)

Ethical issues in access to and delivery of emergency department care in an era of changing reimbursement and novel payment models
por: Kraus, Chadd K., et al.
Publicado: (2020)

Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments Database between 2014 and 2020
por: Murayama, Anju, et al.
Publicado: (2022)

Nosocomial SARS-CoV-2 Infections in Japan: A Cross-sectional Newspaper Database Survey
por: Tani, Yuta, et al.
Publicado: (2020)

Interactions between Australian cancer physicians and the pharmaceutical industry: a qualitative study
por: Pokorny, Adrian M J, et al.
Publicado: (2023)

The Ethics of Itemised Payment for Clinical Research Procedures
por: Evans, H. M., et al.
Publicado: (1993)

Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies
por: Miller, Jennifer E, et al.
Publicado: (2017)

Trends in Industry Payments to Diabetologists and Endocrinologists in the United States During the COVID-19 Pandemic
por: Murayama, Anju, et al.
Publicado: (2022)

Research and Nonresearch Industry Payments for COVID-19 mRNA Vaccines in the United States
por: Murayama, Anju, et al.
Publicado: (2023)

Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study
por: Behdarvand, Behrad, et al.
Publicado: (2019)

‘Lines in the sand’: an Australian qualitative study of patient group practices to promote independence from pharmaceutical industry funders
por: Parker, Lisa, et al.
Publicado: (2021)

Industry payments to allergists and clinical immunologists in the United States during the coronavirus disease 2019 pandemic
por: Murayama, Anju, et al.
Publicado: (2022)

The Trend in Industry Payments During the COVID-19 Pandemic Among Gastroenterologists and Hepatologists in the United States
por: Murayama, Anju, et al.
Publicado: (2022)

Moving towards a better path? A mixed-method examination of China’s reforms to remedy medical corruption from pharmaceutical firms
por: Shi, Jianwei, et al.
Publicado: (2018)

Conflict of interest disclosure slides at the European Society of Cardiology Congress 2016 in Rome: are they displayed long enough to assess their content? A cross-sectional study
por: van Lieshout, Christianne T, et al.
Publicado: (2018)

Underperformance of Reverse-Transcriptase Polymerase Chain Reaction in Japan and Potential Implications From Diamond Princess Cruise Ship and Other Countries During the Ongoing COVID-19 Pandemic
por: Yamamoto, Kana, et al.
Publicado: (2020)

International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
por: Ozieranski, Piotr, et al.
Publicado: (2023)

Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019
por: Mamada, Hanano, et al.
Publicado: (2023)

Social isolation and cancer management – advanced rectal cancer with patient delay following the 2011 triple disaster in Fukushima, Japan: a case report
por: Ozaki, Akihiko, et al.
Publicado: (2017)

Woman Editors-in-Chief of English-Language Medical Journals Published by the Japanese Professional Medical Associations
por: Harada, Kayo, et al.
Publicado: (2021)

Long-term Health Risks of Cancer in Ukraine: Insights from the 2011 Fukushima Triple Disaster Experience
por: Kaneda, Yudai, et al.
Publicado: (2022)

Mental distress in a clinical nurse due to a false‐positive COVID‐19 antibody test result during the COVID‐19 epidemic in Japan: A case report
por: Shimazu, Yuzo, et al.
Publicado: (2021)

CTS certified technology specialist exam guide
por: Grimes, Brad
Publicado: (2013)

CTS Certified Technology Specialist Exam Guide
por: AVIXA Inc
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_54pp93b3rpahokj4ssj2qee64e